Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.

Date publication

octobre 2019

Journal

Pediatric blood & cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal

Tous les auteurs :
Le Teuff G, Castaneda-Heredia A, Dufour C, Jaspan T, Calmon R, Devos A, McHugh K, Leblond P, Frappaz D, Aerts I, Zwaan CM, Ducassou S, Chastagner P, Verschuur A, Corradini N, Casanova M, Rubie H, Riccardi R, Le Deley MC, Vassal G, Geoerger B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31595663

Résumé

To assess objective response after two cycles of temozolomide and topotecan (TOTEM) in children with refractory or relapsed miscellaneous extracranial solid and central nervous system (CNS) tumors, including medulloblastoma and primitive neuroectodermal tumors (PNET).

Mots clés

Bayesian analysis, medulloblastoma, pediatric solid tumors, temozolomide, topotecan

Référence

Pediatr Blood Cancer. 2019 Oct 8;:e28032